Health
Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-Clinical Studies – HospiMedica
Johnson & Johnson’s (New Brunswick, NJ, USA) lead vaccine candidate has successfully protected monkeys against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies.
Johnson & Johnsons (New Brunswick, NJ, USA) lead vaccine candidate has successfully protected monkeys against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies.The companys investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by neutralizing antibodies, successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates…
-
Noosa News22 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime
-
General15 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News16 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General17 hours agoPerth man charged after investigation into organised crime and tobacco store attacks